Flow cytometric crossmatch and early pregnancy loss in women with a history of recurrent spontaneous abortions who underwent paternal leukocyte immunotherapy

Article Abstract:

Two-color flow cytometric crossmatch may be an effective method for predicting pregnancy outcome in women who are being treated with paternal leukocyte immunotherapy. Leucocyte immunotherapy is used to treat women who have had repeated miscarriages for an unknown cause. This treatment involves injecting leukocytes from the baby's father into the mother. Two-color flow cytometric crossmatch was used to examine the development of immunoglobulin G (IgG) antibodies against the father's leukocytes in 69 women who had a history of miscarriages. Of 46 subsequent pregnancies, 35 were in women who were positive for the development of IgG antibodies, and 11 were in women who were negative. Seventeen percent of the women with a positive flow cytometric crossmatch had a miscarriage, compared with 64% of those with a negative flow cytometric crossmatch.

Flow cytometry, Miscarriage, Immunotherapy, Leukocytes, White blood cells

---

A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry

Article Abstract:

Endometrial cancer affects the cells lining the uterus. Sample cells removed from the uterus are usually sent to a laboratory to determine the type of cancer cell. The process of making a diagnosis based on microscopic evaluation is sometimes difficult. In an effort to find a diagnostic method which distinguishes between cell types, a new monoclonal antibody, MSN-1, was developed. Monoclonal antibodies are laboratory-produced identical antibodies that can be used to test for specific cell types. This antibody can help distinguish between the normal endometrial cells and endometrial cancer cells: the monoclonal antibodies reacted with 90 percent of the endometrial cancer cells. This method can thus be used to supplement current cancer detection methods. (Consumer Summary produced by Reliance Medical Information, Inc.)

Diagnosis, Endometrial cancer, Monoclonal antibodies

---

Immunohistochemistry of vascular changes in leuprolide acetate-treated leiomyomas

Article Abstract:

Leuprolide acetate treatment of benign uterine tumors may cause narrowing and inflammation of blood vessels due to buildup of fatty substances. Researchers reviewed the medical records of two women who were treated with leuprolide acetate to shrink benign uterine tumors before surgical removal. Analysis of the tumors showed blood clots that blocked blood vessels, vascular inflammation, and areas of dead tissue. Deposits of immune system proteins were also found. Leuprolide acetate decreases estrogen and progesterone levels, which may lead to atherosclerosis. Prospective patients should be advised of the risks of leuprolide acetate treatment.

Causes of, Chemotherapy, Leiomyoma, Leuprolide, Vasoconstriction

Similar abstracts:

• Abstracts: Multivariate analysis of recurrence after anterior resection for colorectal carcinoma
• Abstracts: Continuing care for cancer pain relief with oral morphine solution: one-year experience in a regional cancer center
• Abstracts: Biochemical and morphological changes in the digestive tract of rats after prenatal and postnatal malnutrition
• Abstracts: Heparin therapy during pregnancy; risks to the fetus and mother. Detection of previous proximal venous thrombosis with Doppler ultrasonography and photoplethysmography
• Abstracts: Anesthetic management of labor in a patient with dextrocardia, congenitally corrected transposition, Wolff-Parkinson-White syndrome, and congestive heart failure

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.